文献速递淋巴瘤

利用循环肿瘤DNA对经典霍奇金淋巴瘤进行综合遗传学研究

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.
PubMed 文献 · Blood · 2025-01-01

本研究利用循环肿瘤DNA(ctDNA)分析经典霍奇金淋巴瘤(cHL)的遗传学特征,识别出两种遗传亚型:一种占64%的病例突变负荷较高且与活化诱导胞苷脱氨酶及微卫星不稳定特征相关,另一种占36%的病例表现为染色体不稳定伴更多体细胞拷贝数改变。全基因组倍增在cHL中较其他B细胞肿瘤更常见,并成为接受Adriamycin(多柔比星)-bleomycin(博来霉素)-vinblastine(长春碱)-dacarbazine(达卡巴嗪)方案治疗患者的预后生物标志物。非编码调控突变在86%的cHL中高发,30%病例存在涉及BCL6基因的复发性体细胞表达数量性状位点(seQTL)。

要点

  • ctDNA分析识别出cHL两种遗传亚型:64%病例突变负荷高伴AID及MSI特征,36%病例染色体不稳定伴更多SCNA。
  • 全基因组倍增在cHL中较其他B细胞肿瘤更常见,并为接受ABVD方案治疗患者的预后生物标志物。
  • BCL6 seQTL见于30%病例,BCL6表达见于68%病例,降解BCL6可去抑制其靶基因并损害增殖。

核心结论

  • ctDNA分析揭示了cHL的遗传学异质性,识别出两种遗传亚型及全基因组倍增的预后价值,并提示ctDNA可用于区分治疗后PET/CT阳性病灶的性质。

研究设计与样本

  • 本研究利用循环肿瘤DNA对经典霍奇金淋巴瘤进行遗传学分析。

主要发现

  • 64%的病例为一种遗传亚型,表现为较高突变负荷及较高比例的活化诱导胞苷脱氨酶和微卫星不稳定特征相关突变;36%的病例为另一种亚型,表现为染色体不稳定伴更多体细胞拷贝数改变。
  • 全基因组倍增在cHL中较其他B细胞肿瘤更常见,并成为接受Adriamycin(多柔比星)-bleomycin(博来霉素)-vinblastine(长春碱)-dacarbazine(达卡巴嗪)方案治疗患者的预后生物标志物。
  • 非编码调控突变在86%的cHL中高度流行,与弥漫性大B细胞淋巴瘤中的非编码调控突变相似。
  • 涉及BCL6基因的复发性体细胞表达数量性状位点(seQTL)见于30%的病例,该seQTL与可及染色质一致且H3K27乙酰化增加,破坏PRDM1结合,并与cHL细胞中BCL6表达共发生。
  • 68%的病例观察到BCL6弱至强表达,BCL6表达在cHL和生发中心B细胞中与基因抑制的关联相似;降解BCL6后,cHL中直接结合并受BCL6调控的核心基因集去抑制,且增殖受损。

关键数值与推荐

  • 64%的病例为突变负荷较高的遗传亚型,36%的病例为染色体不稳定伴更多体细胞拷贝数改变的亚型。
  • 非编码调控突变在86%的cHL中高度流行。
  • BCL6 seQTL见于30%的病例,BCL6表达见于68%的病例。

临床怎么用

  • ctDNA分析被建议作为区分治疗后模糊的正电子发射断层扫描/计算机断层扫描(PET/CT)阳性病灶的工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study analyzed the genetics of classic Hodgkin lymphoma (cHL) by using circulating tumor DNA (ctDNA). Two genetic subtypes were identified, differing in genetic instability mechanisms: one subtype (64% of cases) showed a higher mutation load and a higher fraction of mutations associated with activation-induced cytidine deaminase and microsatellite instability signatures, whereas the other subtype (36% of cases) exhibited chromosomal instability with more somatic copy number alterations. Whole-genome duplication was more common in cHL compared with other B-cell tumors and emerged as a prognostic biomarker for patients undergoing Adriamycin (doxorubicin)-bleomycin-vinblastine-dacarbazine-based therapy. Noncoding regulatory mutations, similar to those in diffuse large B-cell lymphoma, were highly prevalent in 86% of cHL. A recurrent somatic expression quantitative trait locus (seQTL) involving the BCL6 gene was found in 30% of cases. The seQTL of BCL6 aligned with accessible chromatin and increased H3K27 acetylation in cHL, disrupted PRDM1 binding, and co-occurred with BCL6 expression in cHL cells. Weak to strong expression of BCL6 was observed in 68% of cases, and BCL6 expression associated with gene repression similarly in cHL and germinal center B cells. After BCL6 degradation, the core set of genes directly bound and regulated by BCL6 was derepressed in cHL, and proliferation was impaired. The number and clonality of neoantigens was associated with tumor microenvironment type and response to checkpoint blockade. Finally, ctDNA analysis was suggested as a tool to distinguish ambiguous positron emission tomography/computed tomography-positive lesions after treatment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pirosa MC, Bruscaggin A, Terzi di Bergamo L, et al. A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA. Blood. 2025. PMID: 40359477. doi:10.1182/blood.2024027355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。